FreeScore your brand plan before management does. Send me the scorecard
In short: a patient journey map shows the path a person with a condition follows, from the first symptoms to diagnosis, treatment and long-term management, together with the doctors, pharmacists and family members who shape each step. Build it from several sources (patient interviews, professional input, prescription or claims data where permitted, social listening and patient support programme data), with proper consent and a plan for reporting any side effects that surface. Then find the two or three stages where patients are lost or delayed, and turn them into brand actions with an owner, a channel and a measure.
Most pharma brand plans describe the doctor in detail and the patient in one line. The doctor gets segments, call plans and messages. The patient gets an age range and a diagnosis. Yet the outcome the brand depends on is created by the patient: whether they come forward with their symptoms, whether they fill the prescription, whether they are still taking the medicine months later. A brand that only understands the moment of prescribing sees a small slice of the story.
A patient journey map fixes that. It puts the whole path on one page, shows where patients stall or drop out, and shows who could help at each point. This guide explains what a patient journey map is, the stages most maps use, how to build one step by step, how to turn it into actions, and gives you a template you can copy and a worked example for a fictional brand. If your products are mainly bought without a prescription, the guide to consumer insights for consumer healthcare covers the shopper journey from trigger to repeat purchase; this article focuses on conditions where a diagnosis and a prescriber are part of the path.
What Is a Patient Journey Map?
Short answer: a patient journey map is a structured picture of the path a person with a condition follows, stage by stage, showing what they do, think and feel, who else is involved, the barriers they meet, and the moments where support changes what happens next. It is built from evidence, not from the brand team’s assumptions.
The word “map” matters. A good map is not a funnel with percentages at each step, and it is not a list of the brand’s touchpoints. It describes the patient’s experience in the patient’s terms, then lays the healthcare system and the brand on top of it. Where the two do not meet, there is usually a gap the brand can help close.
Three journeys are often confused in pharma, and it helps to separate them before you start.
| Journey | Whose path it follows | Main question | Typical use |
|---|---|---|---|
| Patient journey | A person living with a condition, and often their caregiver | How does someone move from first symptoms to long-term management, and where do they get stuck? | Prescription medicines, chronic conditions, disease awareness, patient support |
| Consumer journey | A shopper choosing a health product they can buy without a prescription | How does a need turn into a purchase and a repeat purchase? | OTC medicines, vitamins, dermo-cosmetics, personal care |
| Customer journey | A professional or business customer: a doctor, pharmacist, hospital or account | How does this customer learn about, adopt and keep using the brand? | HCP engagement, key account management, omnichannel planning |
In practice the three overlap. A patient with a chronic condition may also be a consumer in the pharmacy, buying something alongside the prescription, and the doctor who prescribes is a customer with a journey of their own. The patient journey map is the one that ties them together, because it shows where each professional enters the patient’s path and what the patient needs from them at that moment. The professional side is covered in more depth in the guide to HCP digital engagement.
What Are the Stages of the Patient Journey?
Short answer: seven stages cover most conditions: awareness of symptoms, seeking help, diagnosis, the treatment decision, starting treatment, adherence and persistence, and ongoing management or a switch. Each stage has a parallel layer of doctor and pharmacist touchpoints, and each ends with an event that moves the patient on or holds them back.
The stage names vary between companies and therapy areas. Acute conditions compress the journey into days; chronic conditions stretch it over years and loop back from management to a new treatment decision. Use the structure below as a starting point and adapt it to the condition you are mapping.
| Stage | What the patient experiences | Doctor touchpoints | Pharmacist touchpoints |
|---|---|---|---|
| 1. Awareness of symptoms | Notices something is wrong, explains it away, searches online, talks to family | Usually none yet, unless picked up during a visit for something else | Often the first professional asked, sometimes for a quick remedy |
| 2. Seeking help | Decides the symptoms are serious enough to see someone; chooses where to go | Primary care or a specialist, depending on access and habit | Advises whether to see a doctor; may refer |
| 3. Diagnosis | Tests, waiting, possibly more than one doctor; relief or fear when a name is given | Assessment, tests, referral to a specialist where needed | Limited, but may answer questions about the condition |
| 4. Treatment decision | Hears the options, weighs worries about side effects, cost and daily routine; may consult family | Explains options and prescribes in line with guidelines and the patient’s situation | None yet in most systems |
| 5. Starting treatment | Fills the prescription (or does not), learns how to take or use the medicine, first experience of it | May follow up on early tolerability | Dispenses, explains how to take it, answers first questions; a key moment |
| 6. Adherence and persistence | Builds a routine or struggles to; feels better and wonders whether to stop; refills | Reviews progress at follow-up visits | Sees the patient at each refill; often first to notice gaps |
| 7. Ongoing management or switch | Lives with the condition over time; may need a change of treatment if it is not working or not tolerated | Reviews control, adjusts or switches treatment | Continues to dispense and counsel; may flag concerns to the doctor |
Two features of this table deserve attention. First, the pharmacist appears at both ends of the journey: before the doctor, when the patient is still deciding whether the symptoms matter, and after the doctor, at every refill. Many brand plans ignore both. Second, the doctor is mostly present at decision points, while the patient lives the long stretches in between alone or with family. Those stretches are where many journeys quietly end.
Adherence and persistence are worth separating. Adherence describes whether the patient takes the medicine as prescribed (the right dose, at the right time). Persistence describes whether they keep taking it over the intended period. A patient can be perfectly adherent for a few weeks and then stop altogether. The barriers behind each are often different, so the map should treat them as two questions.
How Do You Build a Patient Journey Map, Step by Step?
Short answer: define the scope, write down what the team already believes, gather evidence from several sources with consent and a safety reporting plan in place, draft the map stage by stage, validate it with patients and professionals, and mark every gap as a question. The method matters more than the design of the final page.
Step 1: Define the scope
Decide which condition, which patient group and which market the map covers. “Patients with the condition” is too broad if newly diagnosed patients and those who have lived with it for years follow different paths. Decide also where the journey starts and ends. For a chronic condition, it may start before diagnosis and never end; for a short treatment course, it may end at recovery. Write the scope at the top of the map so nobody stretches it later.
Step 2: Write down the team’s current beliefs
Before any research, ask the brand, medical, sales and market access teams to sketch the journey as they believe it is. Capture every assumption: where patients first go, why they delay, what doctors say at diagnosis, why patients stop. This hypothesis map is useful for two reasons. It shows the research where to look, and it lets you show the team, at the end, which of their beliefs the evidence supported and which it did not.
Step 3: Gather evidence from several sources
No single source sees the whole journey. Combine them, and note on the map which source each finding comes from.
- Qualitative interviews with patients and caregivers. The core of the map. In-depth interviews, conducted by a trained researcher, let patients describe the journey in their own words: the moment they noticed symptoms, the conversations at diagnosis, the first weeks of treatment. Include caregivers where they play a role. Ask about feelings and practical obstacles, not only events.
- Input from doctors, pharmacists and nurses. Professionals see many patients and can describe common patterns, typical delays and the questions patients ask. Their view is valuable, but it is their view: they rarely see the patients who never come back. Speak to professionals at different points of the journey, not only specialists.
- Claims or prescription data, where available. Where such data exists and its use is permitted, it can show the sequence of treatments, the time between steps and patterns of refills and discontinuation. In many markets this data is limited or fragmented. Use what is available, respect its terms of use, and do not stretch it beyond what it measures.
- Social listening. Public patient forums, social media and online questions show how people talk about symptoms and treatment when no professional is present. Search in the languages patients actually use. Treat it as a source of language and themes, not of measurement, and follow the platform rules and your company’s policy on monitoring public content.
- Patient support programme data. If the company runs a patient support programme, its records of the questions patients ask and the reasons they give for stopping can be among the richest sources. Use it only within the consent patients gave when they enrolled, and through the people authorised to handle it.
Step 4: Get the ethics, consent and safety reporting right
Patient journey research involves people talking about their health, so it carries obligations that ordinary market research may not. Settle these before fieldwork starts, with the medical, compliance and data protection functions.
- Informed consent. Participants should know who is running the research, what it is for, how their information will be stored and used, and that they can withdraw at any time.
- Data protection. Health information is sensitive personal data in most jurisdictions. Collect only what you need, anonymise findings, and follow the data protection law of each country in the study.
- No promotion inside research. The discussion guide must not promote a product or steer participants towards one. Research and promotion are separate activities with separate rules.
- Pharmacovigilance reporting. When a company runs or sponsors research, a side effect or other adverse event mentioned by a participant usually has to be reported to the company’s safety team within the timeline its procedure sets. Train every interviewer and agency on this before fieldwork, include a short reporting instruction in the discussion guide, and agree how reports will be forwarded. Check the requirements that apply in each market with your pharmacovigilance team.
Step 5: Draft the map stage by stage
Lay the evidence out against the stages. For each stage, fill in the same rows: what the patient does, what they think and feel, who else is involved, the doctor and pharmacist touchpoints, the barriers, the moment that matters most, and the evidence behind each statement. Keep the language close to what patients said. “I thought it was just tiredness” tells the team more than “low symptom recognition”.
Step 6: Validate and mark the gaps
Show the draft to a small number of patients and professionals who were not part of the original research and ask what is missing or wrong. Then compare the final map with the hypothesis map from step 2. Where the evidence is thin, write the gap as a question (“We do not yet know why patients stop after the first refill”) rather than filling it with a guess. A map with honest gaps is more useful than a complete map built on assumptions.
FreeScore your brand plan before management does. Send me the scorecard
Which Barriers and Moments Matter Most in the Patient Journey?
Short answer: barriers fall into a few families: not recognising symptoms, delay in seeking help, difficult diagnosis, fears about treatment, practical obstacles to starting, and fading motivation over time. The moments that matter are the points where a patient decides to move on, wait or stop. Those are where support has the most effect.
A barrier is anything that slows or stops the patient. A moment that matters is a point where the patient makes a decision, often without knowing it is one, that shapes the rest of the journey. The table below lists the barrier families that appear in many conditions and the questions to ask about each.
| Barrier family | Where it appears | Questions to ask in research |
|---|---|---|
| Recognition | Awareness of symptoms | Do patients link the symptoms to a condition? What do they blame instead? |
| Delay and stigma | Seeking help | What makes patients wait? Is the condition something they feel able to talk about? |
| Diagnostic path | Diagnosis | How many visits or doctors before a diagnosis? Where does the path loop? |
| Treatment fears | Treatment decision | What worries patients about treatment: side effects, dependence, cost, a lifelong commitment? |
| Practical obstacles | Starting treatment | Is the medicine available where the patient goes? Do they understand how to take or use it? |
| Fading motivation | Adherence and persistence | Why do patients stop? Do they feel better, feel no difference, or forget? |
| Unmet control | Ongoing management or switch | Do patients and doctors notice when treatment is not working well enough? What triggers a review? |
When you have listed the barriers, rank them. The useful ranking combines two questions: how many patients are affected at this point, and whether anyone, including the brand, can realistically do something about it. A barrier that affects many patients but sits entirely outside the brand’s influence belongs on the map, but not at the top of the action list.
How Do You Turn a Patient Journey Map Into Brand Actions?
Short answer: choose the two or three moments that matter most and that the brand can influence within the rules. For each one, name the barrier, the audience who can remove it, the action, the channel and the measure, then write those actions into the brand plan with an owner and a budget.
A patient journey map that ends in a workshop and a poster has failed. Its value comes from the decisions it changes. The bridge from map to plan is a short table: one row per priority moment.
| Priority moment | Barrier | Audience | Possible action | Measure |
|---|---|---|---|---|
| Seeking help | Symptoms dismissed as normal | Patients and family | Disease awareness content, unbranded where required, that helps people recognise when to see a doctor | [Reach; visits to the symptom checker or guide] |
| Diagnosis | Condition missed in primary care | Primary care doctors | Medical education on recognition and referral, through the medical function | [Doctors reached; feedback] |
| Starting treatment | Patients unsure how to take the medicine | Pharmacists | Approved counselling material and training for pharmacy teams | [Pharmacies trained; counselling materials used] |
| Persistence | Patients stop when they feel better | Patients, doctors and pharmacists | Patient support programme with reminders and education, within the consent given | [Enrolment; persistence within the programme] |
Three rules keep this step honest. First, every action has to fit the regulations of the market: in most countries, prescription medicines cannot be advertised to the public, so patient-facing work is usually unbranded disease awareness or support for patients already prescribed the medicine. Second, the action should serve the patient first. If it would not help the patient without the brand, rethink it. Third, the actions must reach the plan. The map should feed the situation analysis and strategic choices in the pharma brand plan, and the insight at the moment that matters most often becomes the foundation for pharma brand positioning.
What Does a Patient Journey Map Template Look Like?
Short answer: a grid with the seven stages as columns and the same set of rows for each: patient actions, thoughts and feelings, people involved, doctor touchpoints, pharmacist touchpoints, barriers, the moment that matters, brand opportunity and evidence. Copy it into a spreadsheet and fill the brackets from your research.
The template below is laid out with the rows as the stages so it reads well on any screen. In a spreadsheet you may prefer to turn it sideways, with stages across the top. Keep the evidence column whichever way you lay it out: it is what stops the map turning back into a set of assumptions.
Template: patient journey map
| Stage | Patient actions | Thoughts and feelings (in their words) | People involved | Doctor and pharmacist touchpoints | Barriers | Moment that matters | Brand opportunity (within the rules) | Evidence and gaps |
|---|---|---|---|---|---|---|---|---|
| 1. Awareness of symptoms | [What they notice and do first] | [Quote] | [Family, friends, online] | [Pharmacist asked? Doctor seen for something else?] | [Recognition barriers] | [The point they decide it matters] | [Awareness, education] | [Source; open question] |
| 2. Seeking help | [Where they go and when] | [Quote] | [Who influences the decision] | [First professional contact] | [Delay, access, stigma] | [The trigger to book a visit] | [Opportunity] | [Source; open question] |
| 3. Diagnosis | [Tests, visits, referrals] | [Quote] | [Doctors, family] | [Primary care, specialist] | [Missed or slow diagnosis] | [How the diagnosis is explained] | [Opportunity] | [Source; open question] |
| 4. Treatment decision | [Options discussed, decision made] | [Quote] | [Doctor, family] | [Prescriber conversation] | [Fears, cost, routine] | [The question that tips the decision] | [Opportunity] | [Source; open question] |
| 5. Starting treatment | [Fills prescription, first doses] | [Quote] | [Pharmacist, family] | [Dispensing and counselling] | [Availability, understanding] | [First days on treatment] | [Opportunity] | [Source; open question] |
| 6. Adherence and persistence | [Routine, refills, missed doses] | [Quote] | [Family, support programme] | [Refill visits, follow-up] | [Fading motivation, forgetting] | [The point patients consider stopping] | [Opportunity] | [Source; open question] |
| 7. Ongoing management or switch | [Living with the condition] | [Quote] | [Doctor, pharmacist, family] | [Reviews, adjustments] | [Unnoticed poor control] | [What triggers a review] | [Opportunity] | [Source; open question] |
Add a header block above the grid with the scope (condition, patient group, market), the date, the sources used and the owner. Below the grid, keep a short list of the open questions, each with the research that would answer it. That list becomes the insight plan for the next year.
What Does a Patient Journey Map Example Look Like?
Short answer: below is a condensed map for a fictional brand in a fictional chronic condition. It shows how the template reads once filled in and how two priority moments become actions. It contains no statistics, because real figures must come from your own research and data.
Important: everything in this example is fictional. “Condition C” is an invented chronic condition and “Brand M” an invented once-daily tablet used to treat it. The example illustrates the method only. It is not medical information and does not describe any real condition, product or company.
The scope
Adults recently diagnosed with Condition C, treated in primary and specialist care, in one market. The journey starts with the first symptoms and runs through the first year of treatment.
The map, condensed
| Stage | What the research suggested | Barrier | Moment that matters |
|---|---|---|---|
| Awareness of symptoms | Patients described the early symptoms as tiredness or stress and tried home remedies first | Recognition | A family member says “you should get that checked” |
| Seeking help | Many asked a pharmacist first, who suggested seeing a doctor | Delay | The pharmacist’s referral |
| Diagnosis | Some patients saw more than one doctor before the diagnosis was made | Diagnostic path | Being referred for the right test |
| Treatment decision | Patients worried about taking a medicine every day for a long time | Treatment fears | How the doctor explains why long-term treatment matters |
| Starting treatment | Patients had questions about when to take the tablet and what to expect in the first weeks | Understanding | The first conversation at the pharmacy |
| Adherence and persistence | Patients who felt no difference in the early weeks questioned whether the tablet was working | Fading motivation | The second or third refill |
| Ongoing management | Follow-up visits focused on new complaints rather than on how well the condition was controlled | Unmet control | The annual review |
Open questions. The research did not show how many patients stop treatment, or when. The team wrote this down as a gap and planned to look for prescription data in the market, with a decision to rely on the patient support programme’s own records if none was usable.
From map to actions
The team chose two priority moments: the first conversation at the pharmacy and the early refills. Both sat in stages the brand could influence within the rules, and both were points where patients described being unsure.
| Moment | Action | Owner | Measure |
|---|---|---|---|
| First conversation at the pharmacy | Approved counselling guide and short training for pharmacy teams on starting patients on Brand M: when to take it, what to expect, when to contact the doctor | Medical and trade marketing | [Pharmacies trained; guide used; feedback from pharmacy teams] |
| Early refills | Patient support programme for prescribed patients who opt in: reminders and education on why treatment continues even when changes are not felt | Brand and patient services | [Enrolment; persistence within the programme] |
| Treatment decision (secondary) | Medical education for doctors on discussing long-term treatment, led by the medical function | Medical | [Doctors reached; feedback] |
Every number in the measures column is a placeholder, to be set from a real baseline. The example shows the shape of the work, not the results it would achieve.
What Should You Consider When Mapping the Patient Journey in Saudi Arabia and the GCC?
Short answer: give the family its own row, treat the pharmacy as a likely first stop as well as the place of dispensing, map public and private care paths separately, research in Arabic as well as English, and follow local rules on promotion, data protection and safety reporting.
The method is the same everywhere, but some features of the Gulf markets change what you should look for. Treat these as prompts for your research, not as findings.
- The family’s role in decisions. Health decisions are often discussed with, and sometimes made by, family members. A spouse, a parent or an adult child may notice the symptoms, book the appointment or manage the medicines. Give the family its own row in the map and consider interviewing caregivers alongside patients.
- The pharmacy as the first stop. Pharmacies are easy to reach in the region, and many people ask a pharmacist before they see a doctor. That makes the pharmacist important at the awareness and seeking-help stages, not only at dispensing. The guide to pharma marketing strategy covers how the pharmacy channel fits into the wider plan.
- Public and private care paths. Patients may move between government and private providers, and the journey can look different in each. Map the paths separately where they diverge.
- Language. Patients may describe symptoms differently in Arabic and English, and online conversations happen in both. Run interviews and social listening in the language the patient group actually uses, with Arabic-speaking researchers.
- Rules. Advertising prescription medicines to the public is not allowed in Saudi Arabia, and promotional material for healthcare professionals must follow the applicable promotional code and the company’s approval process. Personal data, including health data, falls under the country’s data protection law, and adverse events must be handled through the company’s pharmacovigilance system in line with SFDA requirements. Involve the medical, compliance and safety teams from the start.
What Are the Most Common Mistakes in Patient Journey Mapping?
Short answer: building the map from internal opinions, mapping the brand’s touchpoints instead of the patient’s experience, stopping at the prescription, filling gaps with invented numbers, skipping consent and safety planning, and leaving the map out of the brand plan.
- A map built in a workshop. A journey drawn only from the team’s experience repeats what the team already believes. Use it as the hypothesis, then test it with patients.
- Mapping the brand, not the patient. A map that starts with “rep visit” and “detail aid” describes the company’s activity. Start with what the patient does and feels, then add the touchpoints.
- Stopping at the prescription. For many medicines, the hardest part of the journey starts after the first prescription. A map that ends there misses starting, adherence and persistence.
- Ignoring the pharmacist and the family. Both shape the journey at several stages. Leaving them out hides some of the most practical opportunities.
- Invented numbers. Percentages copied from another market, another condition or an old study look precise and mislead. Use real, dated data from your own market or leave a placeholder and a question.
- No consent or safety plan. Research that starts before consent, data handling and adverse event reporting are agreed creates legal and ethical risk and may have to be repeated.
- One map for every patient. Newly diagnosed and long-term patients, or patients in different care settings, may follow different paths. Split the map where the paths really differ.
- A poster, not a plan. If no action in the brand plan can be traced back to the map, the map has not done its job.
Key Takeaways
- A patient journey map follows a person with a condition from first symptoms to long-term management, with the people who shape each step
- It differs from the consumer journey (a shopper buying without a prescription) and the customer journey (a professional or account)
- Seven stages cover most conditions; map the doctor and the pharmacist alongside the patient at each one
- Build it from several sources, with consent, data protection and a pharmacovigilance reporting plan in place before fieldwork
- Rank barriers by how many patients they affect and whether anyone can act on them
- Turn the two or three most important moments into actions with an owner, a channel and a measure in the brand plan
- Leave placeholders and questions where the evidence is missing; never fill the gaps with invented numbers
Frequently Asked Questions
What is a patient journey map?
A patient journey map is a structured picture of the path a person with a condition follows, from noticing the first symptoms to diagnosis, treatment and long-term management. For each stage it records what the patient does, thinks and feels, who else is involved (family, doctors, pharmacists, nurses), the barriers they meet, and the moments where the right support could change what happens next.
What is the difference between a patient journey and a customer journey?
A customer journey follows a buyer through choosing and buying a product. A patient journey follows a person through a health condition, where many decisions are made or shared by a doctor, the product may be prescribed rather than chosen, and the most important part often comes after the first prescription: starting treatment, staying on it, and managing the condition over time.
What are the stages of a patient journey?
A common structure has seven stages: awareness of symptoms, seeking help, diagnosis, the treatment decision, starting treatment, adherence and persistence, and ongoing management or a switch. The names vary between companies and conditions, but the logic stays the same: each stage ends with a decision or an event that moves the patient forward, holds them back, or makes them drop out.
Which sources do you need to build a patient journey map?
Combine qualitative interviews with patients and caregivers, input from doctors, pharmacists and nurses, claims or prescription data where it is available and permitted, social listening, and data from any patient support programme the company runs. Each source sees part of the journey. The map becomes reliable when the sources are compared and the gaps between them are marked as questions to answer.
Do pharma companies need patient consent for journey research?
Yes. Patients and caregivers who take part in interviews or other research must give informed consent, know who is running the research and how their information will be used, and be able to withdraw. Personal health data must be handled under the data protection rules of the country concerned. Research involving patients should also go through the company's medical and compliance review before it starts.
What happens if a patient mentions a side effect during journey research?
If a company runs or sponsors the research, an adverse event mentioned by a participant usually has to be passed to the company's pharmacovigilance team within the timeline its safety procedure sets. Interviewers and agencies should be trained on this before fieldwork begins, and the discussion guide should say how such a mention is recorded and forwarded.
How do you turn a patient journey map into brand actions?
Pick the two or three stages where patients are lost or delayed and where the brand can act within the rules. For each one, name the barrier, the audience who can remove it (patient, caregiver, doctor or pharmacist), the action, the channel and the measure. Then place those actions in the brand plan with an owner and a budget, so the map changes what the team does.
How often should a patient journey map be updated?
Review it at least once a year with the brand plan, and sooner when something material changes: a new guideline, a new competitor, a change in how the medicine is reimbursed or dispensed, or new findings from a patient support programme. Mark each part of the map with the date and the source of its evidence so the team knows which parts are getting old.
What to Do Next
Copy the template into a spreadsheet and fill it in this week with what your team believes today, marking every cell that has no evidence behind it. That gives you the hypothesis map and the list of questions your research needs to answer. Then agree consent, data handling and safety reporting with your medical and compliance colleagues before you speak to a single patient.
When the map is ready, take its priority moments into the pharma brand plan, and if your brand is also bought over the counter, compare it with the consumer journey in the guide to consumer insights for consumer healthcare.
